Arcus Biosciences

• NCT07283848

  Collaborator, Phase 2, Withdrawn, 0 people, 16 Dec 2025

• NCT06919991

  Phase 1, Completed, 14 people, 9 Apr 2025

• NCT05891171

  Phase 1, Active, not recruiting, 40 people, 6 Jun 2023

• NCT05688215

  Collaborator, Phase 1/2, Recruiting, 56 people, 18 Jan 2023

• NCT05633667

  Collaborator, Phase 2, Active, not recruiting, 192 people, 1 Dec 2022

• NCT05568095

  Phase 3, Completed, 1,040 people, 5 Oct 2022

• NCT05502237

  Collaborator, Phase 3, Active, not recruiting, 1,021 people, 16 Aug 2022

• NCT05329766

  Phase 2, Active, not recruiting, 332 people, 15 Apr 2022

• Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

  Phase 2, Active, not recruiting, 169 people, 3 Feb 2021

• NCT03846310

  Phase 1, Completed, 77 people, 19 Feb 2019

• NCT03821246

  Collaborator, Phase 2, Recruiting, 68 people, 29 Jan 2019

Sources: clinicaltrials.gov

• Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study

  Consulting or advice, 22 Sept 2026

• From screening to surveillance: integrated prevention of Helicobacter pylori-associated gastric cancer in the Asia-Pacific region

  Consulting or advice, 17 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov